Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 28 clinical trials
A Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly

The purpose of this trial is to assess the long-term safety of CAM2029 in patients with acromegaly. Patients will be administered CAM2029 subcutaneously once monthly during 12 months. Patients fulfilling trial NCT04076462 will be offered to continue with open-label treatment week 24-52 in this trial.

pituitary
insulin-like growth factor
octreotide
hepatic disease
somatomedin c
  • 60 views
  • 08 Sep, 2021
  • 51 locations
A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly

The purpose of this trial is to assess the efficacy and safety of CAM2029 in patients with acromegaly. Patients will be randomized to either CAM2029 or placebo administered subcutaneously once monthly during 6 months.

insulin-like growth factor
octreotide
hepatic disease
somatomedin c
lanreotide
  • 15 views
  • 03 Jul, 2021
  • 50 locations
Randomized Evaluation of Octreotide Versus Compazine for Emergency Department Treatment of Migraine Headache

number of neuropetides, which have been implicated in migraine. Native somatostatin is an unstable compound and is broken down in minutes, but octreotide, a somatostatin analogue has a longer

nausea
vomiting
dihydroergotamine
pain relief
headache
  • 286 views
  • 07 Nov, 2020
  • 1 location
Treatment of the Dumping Syndrome With Lanreotide Autogel

Background Somatostatin and octreotide LAR (long-acting analogue) exert a number of inhibitory effects: on gut hormones, but also on gastro-intestinal secretion and motility

  • 0 views
  • 07 Nov, 2020
  • 1 location
Palliative Management of Inoperable Malignant Bowel Obstruction

To identify the role of palliative medical management of inoperable malignant bowel obstruction (MBO) with Octreotide, Dexamethasone and Metoclopramide given together as triple therapy.

  • 0 views
  • 28 Jun, 2021
  • 1 location
Acromegaly Combination Treatment Study

In this study the investigators will evaluate whether combination low dose somatostatin receptor ligand (SRL) and weekly or daily Pegvisomant will attain equivalent control of serum IGF-1 levels at a lower cost, compared to combination high dose SRL and weekly Pegvisomant. Lower doses of therapy will greatly reduce cost of …

dopamine agonists
pituitary
medical therapy
combination therapy
somatomedin c
  • 114 views
  • 25 Jan, 2021
  • 1 location
Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET

The aim of NETTER-2 is to determine if Lutathera in combination with long-acting octreotide prolongs PFS in GEP-NET patients with high proliferation rate tumors (G2 and G3), when given as a

  • 0 views
  • 04 Sep, 2021
  • 40 locations
68Ga-DOTATATE PET for Management of Neuroendocrine Tumors

This is a research study to collect information regarding usefulness of positron emission tomography (PET) scans using a special dye called 68Ga-DOTATATE for patients with neuroendocrine tumours by determining the number of of patients whose clinical management was changed as a result of the scans.

pet/ct scan
conventional imaging
dotatate
positron emission tomography
  • 0 views
  • 25 Jan, 2021
  • 1 location
Stress Hydrocortisone In Pediatric Septic Shock

SHIPSS is a multi-institutional, prospective, controlled, randomized, double-blinded interventional trial that will examine the potential benefits and risks of adjunctive hydrocortisone prescribed for children with fluid and vasoactive-inotropic refractory septic shock. It is hypothesized that adjunctive hydrocortisone will significantly reduce the proportion of children with poor outcomes, defined as death …

continuous infusion
norepinephrine
inotropic agent
antimicrobial agent
  • 18 views
  • 07 Sep, 2021
  • 67 locations
Tolvaptan-Octreotide LAR Combination in ADPKD

levels to wild type levels. The vasopressin antagonist Tolvaptan and the somatostatin analogue Octreotide share a similar renoprotective effect also in human disease. Both medications

vasopressin
tolvaptan
somatostatin
octreotide
renal disease
  • 2 views
  • 25 Jan, 2021
  • 2 locations